N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations

AIDS

Volumn 24, Issue 5, 2010, Pages 659-667

  Radzio, Jessica ^a,b   Yap, Soo Huey ^c,d   Tachedjian, Gilda ^c,e,f   Sluis Cremer, Nicolas ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^c Molecular Interactions Group   (United States)

^d UNIVERSITY OF BALLARAT   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f MONASH UNIVERSITY   (Australia)

Author keywords

Antagonism; HIV 1; N348I; Resistance; Reverse transcriptase; Zidovudine

Indexed keywords

ADENOSINE TRIPHOSPHATE; ARGININE; ASPARAGINE; CYSTEINE; DNA; ISOLEUCINE; LEUCINE; LYSINE; METHIONINE; PRIMER DNA; PRIMER RNA; RIBONUCLEASE H; RNA; RNA DIRECTED DNA POLYMERASE; THYMIDINE DERIVATIVE; TYROSINE; VALINE; ZIDOVUDINE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHEMICAL ANALYSIS; CONTROLLED STUDY; DNA TEMPLATE; ENZYME ACTIVITY; ENZYME PURIFICATION; EXCISION REPAIR; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SIGNAL TRANSDUCTION; VIRUS RECOMBINANT;

EID: 77949362812     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328336781d     Document Type: Article

References (39)

1. Goody RS, Muller B, Restle T. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleotides in vitro and in vivo. FEBS Lett 1991; 291:1-5.
2. Sluis-Cremer N, Tachedjian G. Mechanisms of inhibition of HIV replication by nonnucleoside reverse transcriptase inhibitors. Virus Res 2008; 134:147-156.
3. Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296:827-843.
4. Dornsife RE, St Clair MH, Huang AT, Panella TJ, Koszalka GW, Burns CL, Averett DR. Antihuman immunodeficiency virus synergism by zidovudine (3-azidothymidine) and didanosine (dideoxyinosine) contrasts with their additive inhibition of normal human marrow progenitor cells. Antimicrob Agents Chemother 1991; 35:322-328.
5. Johnson VA, Merrill DP, Videler JA, Chou TC, Byington RE, Eron JJ, et al. Two-drug combinations of zidovudine, didanosine, and recombinant interferon-alpha A inhibit replication of zidovu-dine-resistant human immunodeficiency virus type 1 synergis-tically in vitro. J Infect Dis 1991; 164:646-655.
6. Yarchoan R, Lietzau JA, Nguyen BY, Brawley OW, Pluda JM, Saville MW, et al. A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection. J Infect Dis 1994; 169:9-17.
7. Bridges EG, Dutschman GE, Gullen EA, Cheng YC. Favorable interaction of beta-L(-) nucleoside analogues with clinically approved anti-HIV nucleoside analogues for the treatment of human immunodeficiency virus. Biochem Pharmacol 1996; 51:31-36.
8. Villahermosa ML, Martinez-Irujo JJ, Cabodevilla F, Santiago E. Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. Biochemistry 1997; 36:13223-13231.
9. St Clair MH, Martin JL, Tudor-Williams G, Bach MC, Vavro CL, King DM, et al. Resistance to ddI and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991; 253:1557-1559.
10. Larder BA, Kemp SD, Harrigan PR. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 1995; 269:696-699.
11. Nijhuis M, Schuurman R, de Jong D, van Leeuwen R, Lange J, Danner S, et al. Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. J Infect Dis 1997; 176:398-405.
12. Götte M, Arion D, Parniak MA, Wainberg MA. The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis. J Virol 2000; 74:3579-3585.
13. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The M184V mutation reduces the selective excision of zidovudine 5(-mono-phosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 2002; 76:3248-3256.
14. Miranda LR, Götte M, Liang F, Kuritzkes DR. The L74V mutation in human immunodeficiency virus type 1 reverse tran-scriptase counteracts enhanced excision of zidovudine monophosphate associated with thymidine analog resistance mutations. Antimicrob Agents Chemother 2005; 49:2648-2656.
15. Frankel FA, Marchand B, Turner D, Götte M, Wainberg MA. Impaired rescue of chain-terminated DNA synthesis associated with the L74V mutationin human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 2005; 49:2657-2664.
16. Richman D, Rosenthal AS, Skoog M, Eckner RJ, Chou TC, Sabo JP, Merluzzi VJ. BI-RG-587 is active against zidovu-dine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine. Antimicrob Agents Chemother 1991; 35:305-308.
17. Larder BA. 3-Azido-3-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992; 36:2664-2669.
18. Selmi B, Deval J, Alvarez K, Boretto J, Sarfati S, Guerreiro C, Canard B. The Y181C substitution in 3-azido-3-deoxythymidine-resistant human immunodeficiency virus, type 1, reverse tran-scriptase suppresses the ATP-mediated repair of the 3-azido-3-deoxythymidine 5-monophosphate-terminated primer. J Biol Chem 2003; 278:40464-40472.
19. Basavapathruni A, Bailey CM, Anderson KS. Defining a molecular mechanism of synergy between nucleoside and nonnu-cleoside AIDS drugs. J Biol Chem 2004; 279:6221-6224.
20. Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol 2008; 73:601-606.
21. Romano L, Venturi G, Bloor S, Harrigan R, Larder BA, Major JC, Zazzi M. Broad nucleoside-analogue resistance implications for human immunodeficiency virus type 1 reverse-transcrip-tase mutations at codons 44 and 118. J Infect Dis 2002; 185: 898-904.
22. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW, Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2,3-dideoxy-3-thiacytidine. J Virol 1998; 72:5093-5098.
23. Stoeckli TC, MaWhinney S, Uy J, Duan C, Lu J, Shugarts D, Kuritzkes DR. Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine. Anti-microb Agents Chemother 2002; 46:4000-4003.
24. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, et al. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007; 4:e335.
25. Yap SH, Radzio J, Sluis-Cremer N. Mechanism by which N348I in HIV-1 reverse transcriptase confers dual zidovudine/nevir-apine resistance [abstract #79]. 15th Conference on Retro-viruses and Opportunistic Infections; 3-6 February 2008; Boston, Massachusetts, USA; 2008. p. 15.
26. Meyer PR, Matsuura SE, So AG, Scott WA. Unblocking of chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-dependent mechanism. Proc Natl Acad Sci USA 1998; 95:13471-13476.
27. Ray AS, Murakami E, Basavapathruni A, Vaccaro JA, Ulrich D, Chu CK, et al. Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry 2003; 42:8831-8841.
28. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001; 75:4832-4842.
29. Ehteshami M, Beilhartz GL, Scarth BJ, Tchesnokov EP, McCor-mick S, Wynhoven B, et al. Connection domain mutations N348I and A360V in HIV-1 reverse transcriptase enhance resistance to 3-azido-3-deoxythymidine through both RNase H-dependent and-independent mechanisms.JBiol Chem 2008; 283:22222-22232.
30. Delviks-Frankenberry KA, Nikolenko GN, Boyer PL, Hughes SH, Coffin JM, Jere A, Pathak VK. HIV-1 reverse transcriptase connection subdomain mutations reduce template RNA degradation and enhance AZT excision. Proc Natl Acad Sci USA 2008; 105:10943-10948.
31. Le Grice SF, Grüninger-Leitch F. Rapid purification of homo-dimer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur J Biochem 1990; 187: 307-314.
32. Le Grice SF, Cameron CE, Benkovic SJ. Purification and characterization of human immunodeficiency virus type 1 reverse transcriptase. Methods Enzymol 1995; 262:130-144.
33. Brehm JH, Mellors JW, Sluis-Cremer N. Mechanism by which a glutamine to leucine substitution at residue 509 in the ribonuclease H domain of HIV-1 reverse transcriptase confers zidovudine resistance. Biochemistry 2008; 47:14020-14027.
34. Sluis-Cremer N, Arion D, Parikh U, Koontz D, Schinazi RF, Mellors JW, Parniak MA. The 3-azido group is not the primary determinant of 3-azido-3-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem 2005; 280:29047-29052.
35. Basavapathruni A, Vingerhoets J, de Bethune MP, Chung R, Bailey CM, Kim J, Anderson KS. Modulation of human immunodeficiency virus type 1 synergistic inhibition by reverse transcriptase mutations. Biochemistry 2006; 45:7334-7340.
36. Boucher CA, O'Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, et al. Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J Infect Dis 1992; 165:105-110.
37. Brehm JH, Koontz D, Meteer JD, Pathak V, Sluis-Cremer N, Mellors JW. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3-Azido-3-dideoxythymidine. J Virol 2007; 81:7852-7859.
38. Zelina S, Sheen CW, Mellors JW, Sluis-Cremer N. Residue K70 in HIV-1 reverse transcriptase: a crossroad between excision and discrimination mechanisms of NRTI resistance [abstract #143]. Antivir Ther 2006; 11:S159.
39. Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, et al. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2009; 82:3261-3270.